GANAPLACIDE

/static/temp/default.svg

Search structure


Synonyms	GNF 156 GNF-156 Ganaplacide KAF 156 KAF-156 KAF156 Kaf156
Status
Molecule Category	UNKNOWN
UNII	85VMN9JU7A


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	BUPRVECGWBHCQV-UHFFFAOYSA-N
Smiles	CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN
InChI	InChI=1S/C22H23F2N5O/c1-22(2)21-27-19(14-3-5-15(23)6-4-14)20(26-17-9-7-16(24)8-10-17)28(21)11-12-29(22)18(30)13-25/h3-10,26H,11-13,25H2,1-2H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C22H23F2N5O
Molecular Weight	411.46
AlogP	3.61
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	4.0
Polar Surface Area	76.18
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	30.0

Assay Description	Organism	Bioactivity	Reference
Antimalarial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green fluorescence assay	Plasmodium falciparum	10.0 nM
Antimalarial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green fluorescence assay	Plasmodium falciparum	6.0 nM
Antimalarial activity against Plasmodium vivax assessed as reduction in parasite growth after 72 hrs by SYBR-green based fluorescence assay	Plasmodium vivax	5.5 nM
Antimalarial activity against Plasmodium falciparum assessed as reduction in parasite growth after 72 hrs by SYBR-green based fluorescence assay	Plasmodium falciparum	12.6 nM
Inhibition of CYP3A4 (unknown origin)	Homo sapiens	156.0 nM
Antiplasmodial activity against multidrug-sensitive Plasmodium falciparum NF54 transfected with GFP-Luc infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation pretreated for 48 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by liquid scintillation counting method	Plasmodium falciparum	16.0 nM
Binding affinity to wild type CARL in multidrug-resistant Plasmodium falciparum Dd2 infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay	Plasmodium falciparum Dd2	8.8 nM
Binding affinity to CARL L1073Q mutant in multidrug-resistant Plasmodium falciparum infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay	Plasmodium falciparum	12.6 nM
Binding affinity to CARL A1122E mutant in multidrug-resistant Plasmodium falciparum infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay	Plasmodium falciparum	14.8 nM
Binding affinity to CARL 11072V mutant in multidrug-resistant Plasmodium falciparum infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay	Plasmodium falciparum	15.2 nM
Binding affinity to CARL L1108W mutant in multidrug-resistant Plasmodium falciparum infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay	Plasmodium falciparum	16.4 nM
Binding affinity to CARL V1053G mutant in multidrug-resistant Plasmodium falciparum infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay	Plasmodium falciparum	11.1 nM
Binding affinity to CARL M1050I mutant in multidrug-resistant Plasmodium falciparum infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay	Plasmodium falciparum	14.8 nM
Binding affinity to CARL E1104K mutant in multidrug-resistant Plasmodium falciparum infected in human O-postive erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by SYBR Green 1 staining based fluorescence assay	Plasmodium falciparum	108.4 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL2058833
DrugBank	DB16173
FDA SRS	85VMN9JU7A
Guide to Pharmacology	9946
PubChem	49856296
SureChEMBL	SCHEMBL1047381

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).